We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of Levemir® for the Treatment of Type 1 and 2 Diabetes (PREDICTIVE™)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00655044
First Posted: April 9, 2008
Last Update Posted: October 28, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Novo Nordisk A/S
April 4, 2008
April 9, 2008
October 28, 2016
May 2007
January 2008   (Final data collection date for primary outcome measure)
HbA1C [ Time Frame: after 12 weeks ]
Same as current
Complete list of historical versions of study NCT00655044 on ClinicalTrials.gov Archive Site
Safety [ Time Frame: during treatment ]
Same as current
Not Provided
Not Provided
 
Evaluation of Levemir® for the Treatment of Type 1 and 2 Diabetes
Observational, Safety Study in Subjects Using Levemir® (Insulin Detemir) for the Treatment of Type 1 or Type 2 Diabetes Mellitus
This study is conducted in Europe. The aim of this observational study is to evaluate the incidence of serious adverse drug reactions while using Levemir® under normal clinical practice conditions.
Not Provided
Observational
Observational Model: Case Control
Not Provided
Not Provided
Non-Probability Sample
Type 1 and type 2 diabetes patients
  • Diabetes
  • Diabetes Mellitus, Type 1
  • Diabetes Mellitus, Type 2
Drug: insulin detemir
Safety and effectiveness data collection in connection with the use of drug Levemir in daily clinical practice.
Other Names:
  • Levemir®
  • NN304
Type 1 and type 2 diabetes patients
Intervention: Drug: insulin detemir
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
3637
January 2008
January 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Type 1 diabetes
  • Type 2 diabetes
  • Candidates of use of a basal insulin as part of their diabetes regimen

Exclusion Criteria:

  • Unwilling to adhere to therapy or follow up
  • Pregnancy
Sexes Eligible for Study: All
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
Russian Federation
 
 
NCT00655044
NN304-3514
No
Not Provided
Not Provided
Novo Nordisk A/S
Novo Nordisk A/S
Not Provided
Study Director: Global Clinical Registry (GCR, 1452) Novo Nordisk A/S
Novo Nordisk A/S
October 2016